ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintSite TitleTitle ChevronIcon Twitter
SoftBank

SoftBank CEO's approval rating rises despite historic loss

Son wins 96% shareholder votes, indicating tight grip on tech conglomerate

SoftBank Group CEO Masayoshi Son made clear that he had no intention of leaving the company anytime soon during last week’s shareholder meeting.

TOKYO -- SoftBank Group Chairman and CEO Masayoshi Son won an approval rating of 95.99% at a shareholder meeting last week, highlighting his tight grip over the Japanese technology conglomerate despite presiding over a historic loss.

A resolution to appoint Son and 12 other directors to the SoftBank board was approved on June 25, the details of which were disclosed in a filing on Monday. Son's approval rating was higher than last year's 92.85%.

All 13 members had an approval rating of more than 90%. Rajeev Misra, head of SoftBank's near $100 billion Vision Fund, had the lowest rating of 93.74%.

The figures indicate Son's control over the company despite SoftBank's 961 billion yen ($9 billion) net loss in the year ended March, the widest it has ever reported. The losses have added pressure on Son, whose reputation was already dented by a bet on U.S. office space provider WeWork that turned sour last year.

The solid approval rating is in part thanks to Son's large stake in SoftBank -- he owns about 27%, including indirectly through asset management firms -- as of March, according to public disclosures. SoftBank also completed a 500 billion yen share buyback mid-June and has plans to buy back an additional 2 trillion yen worth of shares. That amounts to more than 20% of SoftBank's market capitalization on Monday.

It may also be a sign that Son's response to demands from some shareholders, including U.S. activist investor Elliott Management, is working. SoftBank added two independent directors and set up a committee, which includes Son and two independent directors, that will make recommendations to board appointments and compensation policies.

During last week's shareholder meeting, Son made clear that he had no intention of leaving anytime soon. "I'm around 62 or 63 years old," he said. "I'll continue as CEO and chairman for another seven or eight years. By the time I'm 69, since medical science is advancing, I might say I'm roughly in my 60s and stay a little longer."

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Get Unlimited access

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends July 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media